Drug Trial Radar · NCT04543331
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
572
Actual
Start
Mar 18, 2020
Primary completion
Nov 17, 2025
Study completion Nov 17, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 10, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC. An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.
Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Diabetic Macular Edema (DME)
Interventions
brolucizumabDrug
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)Time frame: Month 12
- Mean change in visual acuity (VA) under clinic specific routine treatment schemesTime frame: Baseline, month 12
- Morphological CNV-Changes under clinic specific routine treatment schemesTime frame: Baseline, month 12
- Percent of patients maintained on q12w dosing after loading through Week 52Time frame: After loading, month 12
- Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)Time frame: Baseline, month 12
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Aschersleben, Germany
Novartis Investigative Site
Bayreuth, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Breisach, Germany
Novartis Investigative Site
Chemnitz, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Esslingen am Neckar, Germany
Novartis Investigative Site
Glauchau, Germany
Novartis Investigative Site
Homburg, Germany
Novartis Investigative Site
Hösbach, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Marienberg, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Neubrandenburg, Germany
Novartis Investigative Site
Schönebeck, Germany
Novartis Investigative Site
Stralsund, Germany
Novartis Investigative Site
Sulzbach, Germany
Novartis Investigative Site
Torgau, Germany
Novartis Investigative Site
Waren, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Neuburg A.d. Donau, Bavaria, Germany
Novartis Investigative Site
Würzburg, Bavaria, Germany
Novartis Investigative Site
Würzburg, Bavaria, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Göttingen, Lower Saxony, Germany
Novartis Investigative Site
Osnabrück, Lower Saxony, Germany
Novartis Investigative Site
Rostock, Mecklenburg-Vorpommern, Germany
Novartis Investigative Site
Trier, Rhineland-Palatinate, Germany
Novartis Investigative Site
Saarbrücken, Saarland, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Leipzig, Saxony, Germany
Novartis Investigative Site
Schneeberg, Saxony, Germany
Novartis Investigative Site
Halle, Saxony-Anhalt, Germany
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.